苑东生物：EP-0210单抗注射液I期临床试验完成首例受试者给药

Group 1 - The core point of the article is that Yuandong Biotech (688513.SH) announced the completion of the first dosing of its monoclonal antibody drug EP-0210 in a Phase I clinical trial for the treatment of inflammatory bowel disease [2] - The drug EP-0210 is a humanized IgG1 monoclonal antibody targeting the tumor necrosis factor-like ligand 1A (TL1A) [2] - EP-0210 demonstrates superior target activity and in vivo efficacy compared to the foreign competitor RVT-3101 [2]